Deutsche Bank analyst David Hoang raised the firm’s price target on Alkermes (ALKS) to $52 from $40 and keeps a Buy rating on the shares. After speaking with sleep specialists, the firm has increased conviction in ALKS 2680. The orexin-2 receptor agonist candidate is in “pole position” for narcolepsy, the analyst tells investors in a research note. The firm says doctors endorsed a bullish view of the orexin class as a “game-changer” for the treatment of narcolepsy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes price target raised to $35 from $34 at BofA
- Alkermes initiated with a Sector Perform at RBC Capital
- Alkermes upgraded to Neutral from Sell at UBS
- Alkermes: Hold Rating Amid Declining Base Business Value and Optimistic Orexin Outlook
- Regulatory Challenges Pose Significant Risks to Alkermes’ Financial Stability